Precision BioSciences (NASDAQ: DTIL) is one of 138 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Precision BioSciences to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, profitability, earnings and analyst recommendations.
This table compares Precision BioSciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Precision BioSciences Competitors||-4,593.65%||-149.53%||-36.96%|
54.3% of Precision BioSciences shares are owned by institutional investors. Comparatively, 48.8% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 17.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Precision BioSciences and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Precision BioSciences||$22.24 million||-$92.88 million||-3.16|
|Precision BioSciences Competitors||$759.37 million||$139.43 million||3.92|
Precision BioSciences’ rivals have higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent recommendations for Precision BioSciences and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Precision BioSciences Competitors||1296||3844||7766||354||2.54|
Precision BioSciences presently has a consensus price target of $22.17, suggesting a potential upside of 267.00%. As a group, “Biological products, except diagnostic” companies have a potential upside of 48.59%. Given Precision BioSciences’ stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than its rivals.
Precision BioSciences beats its rivals on 7 of the 12 factors compared.
About Precision BioSciences
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.